Search results
Results from the WOW.Com Content Network
Dulaglutide, sold under the brand name Trulicity among others, [8] is a medication used for the treatment of type 2 diabetes in combination with diet and exercise. [9] [10] It is also approved in the United States for the reduction of major adverse cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors.
Albiglutide (trade names Eperzan in Europe and Tanzeum in the US) is a glucagon-like peptide-1 agonist (GLP-1 agonist) drug marketed by GlaxoSmithKline (GSK) for treatment of type 2 diabetes. As of 2017 it is unclear if it affects a person's risk of death. [ 2 ]
Liraglutide, sold under the brand name Victoza among others, is an anti-diabetic medication used to treat type 2 diabetes, and chronic obesity. [6] [7] It is a second-line therapy for diabetes following first-line therapy with metformin. [6] [8] Its effects on long-term health outcomes like heart disease and life expectancy are unclear.
There’s been lots of attention on type 2 diabetes drugs recently, especially since they might also be able to support weight loss. Whether you have type 2 diabetes or obesity, you may have heard ...
A 94% reduction sounds great, he said, but the company didn't reveal the actual figures, so it's unclear if the drug helped 200 people avoid getting diabetes or just two. "They didn't give one bit ...
Semaglutide is an anti-diabetic medication used for the treatment of type 2 diabetes and an anti-obesity medication used for long-term weight management. [23] [24] [25] It is a peptide similar to the hormone glucagon-like peptide-1 (GLP-1), modified with a side chain. [26] [27] It can be administered by subcutaneous injection or taken orally.
The medicine in the diabetes drug Mounjaro helped people with obesity or who are overweight lose at least a quarter of their body weight, or about 60 pounds on average, when combined with ...
The benefits of tirzepatide for the treatment of adult participants with type 2 diabetes were primarily evaluated in five clinical trials. [42] In two of these trials (NCT03954834 and NCT04039503), participants were randomly assigned to receive either tirzepatide or placebo injection weekly. [42]